Mitral Valve Repair with MitraClip Is Safe in High-Risk Patients

Courtesy of Dr. Carlos Fava.

Transcatheter mitral valve repair with MitraClip has shown good results in symptomatic patients with extreme surgical risk in different studies. However, its “real world” benefits have not been studied in depth due to how complex this strategy is compared with other usual procedures.

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

This study analyzed 2952 patients who underwent mitral valve repair with MitraClip and were included in the STS/ACC TVT Registry.


Read also: MitraClip Procedure Can Be Performed without General Anesthesia”.


The mean age was 82 years (over half the patients were male) and patients presented multiple comorbidities. Their functional class was low and half of them were considered fragile. All of them presented high surgical risk (the Society of Thoracic Surgery predicted risk of mortality was 6.1% for mitral repair and 9.2% for mitral replacement).

 

The root cause for mitral regurgitation was degenerative.

 

The most frequent MitraClip implantation site was the A2P2 segment. Patients were implanted with more than one clip in 34% of all cases. As regards mitral regurgitation severity, 61.8%, 31.2%, and 7% of all patients presented ≤1, 2, and ≥3 levels, respectively. Procedural success was 91.8%.


Read also: SOLACI CACI 2017 | How to do a MitraClip simple and fast”.


In-hospital mortality was 2.7%; 4 patients experienced device embolization; major bleeding was 3.9%; stroke was 0.4%; acute myocardial infarction was 0.1%, and the need for surgery was 0.7%.

 

The rates of mortality at 30 days and at 1 year were 5.2% and 25.8%, respectively, and repeat hospitalization for heart failure was 20.2%.

 

The factors associated with mortality or repeat hospitalization for heart failure, after multivariate adjustment, were the following:

  • Old age
  • Low ejection fraction
  • Worse post-procedural mitral regurgitation
  • Chronic obstructive pulmonary disease (COPD)
  • Dialysis
  • Tricuspid regurgitation

 

Conclusion

These findings demonstrate that “real world” transcatheter mitral valve repair was performed in the United States with effectiveness and safety. In that sense, findings may help determine which patients have favorable long-term outcomes with this therapy.

 

Editorial Comment

This “real world” analysis shows that this strategy is feasible and safe in extreme- and high-risk patients, and that its 1-year outcomes are defined by the significant comorbidities present.

 

With greater group experience and new devices, this indication will surely be applied to lower-risk populations.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Outcomes with Transcatheter Mitral Valve Repair in the United States. An STS/ACC TVT Registry Report.

Reference: Paul Sorajja, et al. J Am Coll Cardiol 2017;70:2315-27.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...